XML 46 R34.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Summary of Significant Accounting Policies - License Agreements - LG Chem (Details) $ in Thousands |  | 1 Months Ended | 3 Months Ended
--- | --- | --- | ---
Jan. 04, 2024 USD ($) | Jan. 31, 2024 USD ($) item person | Mar. 31, 2024 USD ($)
Significant Agreements |  |  |
Issuance of common stock as consideration for LGC license |  |  | $ 18,716
L G Chem Ltd |  |  |
Significant Agreements |  |  |
Issuance of common stock as consideration for LGC license | $ 18,700 |  |
License agreement consideration payment | $ 40,000 |  |
Effective date of the license agreement | 18 months |  |
Aggregate payment upon achievement of development and commercial milestones | $ 205,000 |  |
License agreement | L G Chem Ltd |  |  |
Significant Agreements |  |  |
Number of patients | person |  | 28 |
Number of doses participants | item |  | 1 |
Period to check the primary end point of the treatment |  | 98 days |
Period of oral administration |  | 364 days |
Period of route trial |  | 112 days |
Number of enrolled patients | person |  | 5 |
Cash payment |  | $ 40,000 |
Issuance of common stock as consideration for LGC license |  | 18,700 |
License agreement consideration payment |  | $ 40,000 |
Effective date of the license agreement |  | 18 months |
Aggregate payment upon achievement of development and commercial milestones |  | $ 205,000 |
Maximum number of doses participants | item |  | 3 |

X
- Definition Represent the amount of aggregate payment upon achievement of development and commercial milestones. + References No definition available. + Details
Name: | rytm_AggregatePaymentUponAchievementOfDevelopmentAndCommercialMilestones
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of cash payment made for the agreement. + References No definition available. + Details
Name: | rytm_CashPaymentMadeForLicenseAgreement
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The period it takes for the route trial to complete the treatment. + References No definition available. + Details
Name: | rytm_DurationForRouteTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period for which participant will be receiving one dose of the medicine in the signal trial. + References No definition available. + Details
Name: | rytm_DurationForWhichParticipantWillBeReceivingOneDoseInSignalTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The period to check the primary end point of the treatment in the signal trial. + References No definition available. + Details
Name: | rytm_DurationToCheckPrimaryEndPointOfTreatmentInSignalTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of upfront consideration received in cash in license agreement. + References No definition available. + Details
Name: | rytm_LicenseAgreementConsiderationPaymentReceivedInCash
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The lock up period for subsequent cash payment in the agreement. + References No definition available. + Details
Name: | rytm_LockUpPeriodForSubsequentCashPayment
Namespace Prefix: | rytm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The maximum number of doses participants will receive in the signal trial. + References No definition available. + Details
Name: | rytm_MaximumNumberOfDosesParticipantsWillReceiveInSignalTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of doses participants will receive now under the signal trial. + References No definition available. + Details
Name: | rytm_NumberOfDosesParticipantsWillReceiveUnderSignalTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of patients be enrolled under the route trial. + References No definition available. + Details
Name: | rytm_NumberOfPatientsBeEnrolledUnderRouteTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of patients be evaluated under the Signal trial. + References No definition available. + Details
Name: | rytm_NumberOfPatientsBeEvaluatedUnderSignalTrial
Namespace Prefix: | rytm_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Equity impact of the value of new stock issued during the period from license agreement. + References No definition available. + Details
Name: | rytm_StockIssuedDuringPeriodValueNewIssuesLicenseAgreement
Namespace Prefix: | rytm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rytm_LGChemLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rytm_LicenseAgreementAndShareIssuanceAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |